Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • ID: 3927514
  • Report
  • Region: Asia Pacific
  • 112 Pages
  • GBI Research
1 of 5
Asia-Pacific Gastric Cancer Market Set to Experience Strong Growth to $2.7 Billion by 2022

FEATURED COMPANIES

  • AstraZeneca
  • Celgene/Taiho
  • Eli Lilly
  • Gilead Bioscience
  • Jiangsu HengRui Medicine
  • Merck
  • MORE
Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it is difficult to treat until it’s more advanced stages and as a result remains one of the most common causes of cancer-related deaths worldwide. The incidence rate of gastric carcinoma is high in East Asia - particularly China and Japan - compared with Western markets. There are many types of gastric cancer, but adenocarcinoma is the most common type, and is diagnosed in 95% of cases.

The Asia-Pacific (APAC) gastric cancer market is forecast to grow from $1.3 billion in 2015 to $2.7 billion in 2022, at a Compound Annual Growth Rate (CAGR) of 11.4%. Gastric cancer is often a neglected cancer, as it tends to develop slowly over many years. The majority of gastric cancer cases are diagnosed in the later stages in the countries focused on in this report, with the exception of Japan, where the majority of cases are diagnosed at the early stages. The high number of cases diagnosed at stage I in Japan can be attributed to the country’s increased levels of awareness and screening for gastric cancer (Orditura et al., 2014).

As per Gayathri Kanika, “In line with improved diagnosis rates, the anticipated approval of various monoclonal antibodies (mAbs) over the forecast period will drive treatment rates across all lines of therapy and generate higher sales in the gastric cancer market”.

The current treatment landscape of gastric cancer largely comprises generic chemotherapies. However, chemotherapy provides limited clinical benefit, while causing serious side effects. Herceptin (trastuzumab) is the only marketed targeted therapy, and serves as the standard-of-care first-line treatment for HER2-positive patients - HER2-negative gastric cancer patients still receive chemotherapy regimens as the first-line treatment.

The report “Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies” provides an introduction to gastric cancer, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients. An analysis of current treatment algorithms and options are also included.

In depth, this report provides the following analysis:
  • Detailed analysis of the drugs currently marketed for this indication: trastuzumab, ramucirumab, apatinib, nab-paclitaxel and TS-1. It analyzes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, prices and overall competitive strength. The products are also compared in a comprehensive heat map.
  • Analysis of the pipeline for gastric cancer, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the gastric cancer market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015-2022 period. The five APAC markets are covered, and data is presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for the gastric cancer market.
  • Describes the major deals that have taken place in the global gastric cancer market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Celgene/Taiho
  • Eli Lilly
  • Gilead Bioscience
  • Jiangsu HengRui Medicine
  • Merck
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.5.1 Helicobacter Pylori
2.5.2 Oncogenes
2.5.3 Tumor Suppressor Genes
2.5.4 Cell Adhesion Molecules and Metastasis-Related Genes
2.5.5 Cell Cycle Regulators
2.5.6 Microsatellite and Chromosomal Instability
2.5.7 Growth Factor and Cytokines
2.6 Diagnosis
2.6.1 Photofluorography or Barium Study
2.6.2 Endoscopy
2.6.3 Imaging Tests
2.6.4 Endoscopic Ultrasound
2.6.5 Laparoscopy
2.6.6 Laboratory Analysis
2.7 Classification and Disease Staging
2.7.1 Intestinal Subtype
2.7.2 Diffuse Subtype
2.8 Prognosis
2.9 Treatment Guidelines and Options
2.9.1 Surgery
2.9.2 First-Line Therapy
2.9.3 Second-Line Therapy

3 Marketed Products
3.1 Overview
3.2 HER2-Targeted Therapy
3.2.1 Herceptin (trastuzumab) - Roche/Genentech
3.3 Angiogenesis Inhibitors
3.3.1 Cyramza (ramucirumab) - Eli Lilly
3.3.2 Aitan (apatinib) - Jiangsu HengRui Medicine
3.4 Newer Chemotherapies
3.4.1 TS-1 (tegafur, gimeracil, oteracil) - Taiho
3.4.2 Abraxane (nab-paclitaxel) - Celgene/Taiho
3.5 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Opdivo (nivolumab) - Ono Pharmaceutical/Bristol-Myers Squibb
4.4.2 Keytruda (pembrolizumab) - Merck
4.4.3 Perjeta (pertuzumab) - Roche
4.4.4 Napabucasin - Boston Biomedical (subsidiary of Dainippon Sumitomo Pharma)
4.4.5 Lynparza (olaparib) - AstraZeneca
4.4.6 Nimotuzumab - Kuhnil Pharmaceutical/Daiichi Sankyo
4.4.7 Avelumab - Merck
4.4.8 GS-5745 - Gilead Bioscience
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitive Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Stage of Development and Molecule Type
5.3.2 Trial Duration by Stage of Development and Molecular Target
5.4 Summary of Clinical Trial Metrics

6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Market Dynamics
7.1 Drivers
7.1.1 Increasing Prevalence and Treatment Rate Across All Lines of Therapy in the Metastatic Setting
7.1.2 Promising Drug Pipeline Focused on Targeted Therapies
7.1.3 Launch of Premium-Priced Drugs for the Metastatic Setting
7.1.4 Improved Treatment Options that Extend Duration of Therapy
7.1.5 Increasing Screening Programs and Government Reforms
7.2 Barriers
7.2.1 Lack of Development of Pipeline Agents as Pre-operative and Postoperative Treatments for Resectable Gastric Cancer
7.2.2 Patent Expiration of Herceptin and Patient Share Erosion by Trastuzumab Biosimilars
7.2.3 Affordability and Reimbursement Issues in India and China

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Deals by Year
8.2.3 Deals by Stage of Development, Molecule Type and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Investigational New Drug/ Clinical Trial Authorization-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging
Table 2: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 3: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 4: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2016
Table 5: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 6: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 7: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 8: Gastric Cancer Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
Table 9: Gastric Cancer Therapeutics Market, India, Market Forecast, 2015-2022
Table 10: Gastric Cancer Therapeutics Market, China, Market Forecast, 2015-2022
Table 11: Gastric Cancer Therapeutics Market, Australia, Market Forecast, 2015-2022
Table 12: Gastric Cancer Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 13: Gastric Cancer Therapeutics Market, Japan, Market Forecast, 2015-2022

1.2 List of Figures
Figure 1: Gastric Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2004, 2008 and 2012
Figure 2: Gastric Cancer, Stage Grouping
Figure 3: Gastric Cancer, Market Heat Map
Figure 4: Pipeline for Gastric Cancer, Global, 2016
Figure 5: Pipeline for Gastric Cancer by Molecular Target, Global, 2016
Figure 6: Pipeline for Gastric Cancer by Molecular Target by Stage of Development, Global, 2016
Figure 7: Gastric Cancer Therapeutics Market, Asia-Pacific, Opdivo, Market Forecast ($m), 2018-2022
Figure 8: Gastric Cancer Therapeutics Market, Asia-Pacific, Keytruda, Market Forecast ($m), 2019-2022
Figure 9: Gastric Cancer Therapeutics Market, Asia-Pacific, Perjeta, Market Forecast ($m), 2018-2022
Figure 10: Gastric Cancer Therapeutics Market, Asia-Pacific, Napabucasin, Market Forecast ($m), 2018-2022
Figure 11: Gastric Cancer Therapeutics Market, Asia-Pacific, Lynparza, Market Forecast ($m), 2019-2022
Figure 12: Gastric Cancer Therapeutics Market, Asia-Pacific, Nimotuzumab, Market Forecast ($m), 2019-2022
Figure 13: Gastric Cancer Therapeutics Market, Asia-Pacific, Avelumab, Market Forecast ($m), 2020-2022
Figure 14: Gastric Cancer, Pipeline Heat Map
Figure 15: Gastric Cancer, Marketed and Pipeline Product Competitiveness Framework
Figure 16: Gastric Cancer Therapeutics Market, Global, Overall Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 17: Gastric Cancer Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 18: Gastric Cancer Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 19: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type and Stage of Development, 2006-2016
Figure 20: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target and Stage of Development, 2006-2016
Figure 21: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Trial by Stage of Development and Molecule Type, 2006-2016
Figure 22: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Trial by Stage of Development and Molecular Target, 2006-2016
Figure 23: Gastric Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, 2006-2016
Figure 24: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size by Molecular Target by Stage of Development (patients), 2006-2016
Figure 25: Gastric Cancer Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 26: Gastric Cancer Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 27: Gastric Cancer Therapeutics Market, Asia-Pacific, Treatment Patterns (‘000), 2015-2022
Figure 28: Gastric Cancer Therapeutics Market, Asia-Pacific, Market Size ($bn), 2015-2022
Figure 29: Gastric Cancer Therapeutics Market, India, Treatment Patterns (‘000), 2015-2022
Figure 30: Gastric Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
Figure 31: Gastric Cancer Therapeutics Market, India, Market Size ($m), 2015-2022
Figure 32: Gastric Cancer Therapeutics Market, China, Treatment Patterns (‘000), 2015-2022
Figure 33: Gastric Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
Figure 34: Gastric Cancer Therapeutics Market, China, Market Size ($bn), 2015-2022
Figure 35: Gastric Cancer Therapeutics Market, Australia, Treatment Patterns, 2015-2022
Figure 36: Gastric Cancer Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
Figure 37: Gastric Cancer Therapeutics Market, Australia, Market Size ($m), 2015-2022
Figure 38: Gastric Cancer Therapeutics Market, South Korea, Treatment Patterns (‘000), 2015-2022
Figure 39: Gastric Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 40: Gastric Cancer Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 41: Gastric Cancer Therapeutics Market, Japan, Treatment Patterns (‘000), 2015-2022
Figure 42: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
Figure 43: Gastric Cancer Therapeutics Market, Japan, Market Size ($bn), 2015-2022
Figure 44: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 45: Gastric Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year and Aggregate Deal Value ($m), 2006-2016
Figure 46: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development and Deal Value ($m) 2006-2016
Figure 47: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 48: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2016
Figure 49: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Region, 2006-2016
Figure 50: Gastric Cancer Therapeutics Market, Global, Number of Co-development Deals by Year, 2006-February 2016
Figure 51: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2016
Figure 52: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development, 2006-2016
Figure 53: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016 87"
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- AstraZeneca
- Boston Biomedical (subsidiary of Dainippon Sumitomo Pharma)
- Celgene/Taiho
- Eli Lilly
- Gilead Bioscience
- Jiangsu HengRui Medicine
- Kuhnil Pharmaceutical/Daiichi Sankyo
- Merck
- Ono Pharmaceutical/Bristol-Myers Squibb
- Roche
- Taiho
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll